Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

Klein, O; Gao, B; Chan, H; Michael, M; Zielinski, R; So, J; Harris, SJ; Kee, D; Collins, Ian; Lam, W-S; Lyle, M; Underhill, CR; Brown, M; Harrup, RA; Wong, SF; Palmer, JB; Thomas, D; Wilkie, K; Cebon, J; Carlino, MS

Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

journal contribution

posted on 2025-04-23, 22:40 authored by O Klein, B Gao, H Chan, M Michael, R Zielinski, J So, SJ Harris, D Kee, Ian CollinsIan Collins, W-S Lam, M Lyle, CR Underhill, M Brown, RA Harrup, SF Wong, JB Palmer, D Thomas, K Wilkie, J Cebon, MS Carlino

Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

History

Journal

Annals of Oncology

Volume

35

Pagination

S679-S680

Location

Amsterdam, The Netherlands

Publisher DOI

https://doi.org/10.1016/j.annonc.2024.08.1057

Open access

No

ISSN

0923-7534

eISSN

1569-8041

Language

eng

Publication classification

E3.1 Extract of paper

Issue

S2

Publisher

Elsevier

Publication URL

https://doi.org/10.1016/j.annonc.2024.08.1057

Usage metrics

Keywords

Life Sciences & Biomedicine Oncology Science & Technology

Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

History

Journal

Volume

Pagination

Location

Publisher DOI

Open access

ISSN

eISSN

Language

Publication classification

Issue

Publisher

Publication URL

Usage metrics

Categories

Keywords

Licence

Exports